Japan's cannabinoid market is restructuring. CBN — which had become a major commercial segment in the sleep-support and relaxation category — is exiting following the MHLW designation process initiated in 2025. For brands positioned correctly, this represents the most significant single-cannabinoid market opportunity in Japan since CBD was first imported in 2013.
The Size of the Opportunity
Japan's CBN market was estimated at approximately ¥10 billion in FY2024, driven primarily by sleep supplement positioning and high-dose "relaxation" products. That demand does not disappear. Japanese consumers seeking CBN's functional benefits will migrate to the next viable alternative — and that migration is already underway.
Domestic wholesale buyers across supplement retail, natural products distribution, and e-commerce are actively seeking CBG product supply. Inquiry volume at Asayake Inc. for CBG-containing products has increased sharply since Q4 2025. Brands that enter with a compliant, well-documented CBG product now have first-mover positioning in a disrupted market.
CBG's Current Regulatory Position
CBG (cannabigerol) is not currently scheduled under Japan's Cannabis Control Act, the Narcotics and Psychotropics Control Act, or the Stimulants Control Act. It is not under active formal review by the MHLW Pharmaceutical Affairs Council. This is the same regulatory position that CBD occupied before 2013 — unscheduled, with a clear path to import under appropriate documentation.
Important caveat: "Not currently scheduled" does not mean "permanently safe." Japan's regulatory pace has accelerated markedly since 2024. CBG is under informal MHLW observation. Early movers who establish market position while CBG remains unscheduled will be far better positioned if and when regulatory review begins.
Import Requirements for CBG Products
CBG products follow the same import pathway as CBD products under current MHLW policy:
- MHLW import notification required prior to first shipment
- Japan-accredited laboratory CoA required (CBG purity, THC residue per applicable product type limit)
- Product-specific Δ9-THC residue compliance (same three-tier standard as CBD)
- Ingredient disclosure and labeling compliance for Japanese market
The import documentation requirements are substantively the same as for CBD isolate products. Brands with existing Japan market entry infrastructure for CBD can add CBG products to their portfolio with moderate incremental effort.
Product Positioning Considerations
Sleep & Relaxation Replacement
The most direct CBN replacement positioning. CBG has documented interaction with GABA-A receptors and shows anxiolytic effects in preclinical research. Japanese consumer research indicates significant awareness of CBG among former CBN users. "CBN-free, CBG-forward" product concepts are performing well in early consumer testing conducted by domestic brands.
Focus & Cognitive Support
CBG is increasingly positioned in international markets for focus and cognitive performance, differentiated from CBD's broader wellness positioning. This represents a relatively unexplored segment in Japan and may offer premium positioning opportunities distinct from the crowded CBD oil category.
Terpene-Enhanced Formulations
Japanese consumers show strong preference for natural, ingredient-transparent products. CBG combined with Japanese botanical terpenes (hinoki, yuzu, shiso) creates a compelling "Japan-specific" product concept with premium positioning and significantly lower regulatory risk than broad-spectrum formulations.
Why Act Now Rather Than Later
Japan's market entry process takes time. MHLW import notification, Japan-accredited lab testing coordination, and logistics setup typically require 3–6 months from initial decision to first shipment. Brands that begin the process now will be positioned to capture market share during the peak displacement period — when CBN inventory has depleted from domestic channels and consumer demand is actively seeking alternatives.
Brands that wait until the market is clearly established will face established domestic competitors, potentially tighter regulatory scrutiny of CBG, and compressed margins in a more crowded market.
Next step: If you have a CBG product and want a formal assessment of its importability into Japan before committing to inventory or market entry investment, Import Verdict™ is the appropriate first step.